Regeneron and alnylam report promising data from ongoing phase 1 study of aln-hsd in nash patients and healthy volunteers

Target knockdown and safety results support continued clinical development regeneron and alnylam intend to initiate a phase 2 study in late 2022 detailed results to be presented at an upcoming medical congress tarrytown, n.y and cambridge, mass. , sept. 15, 2022 /prnewswire/ -- regeneron pharmaceuticals (nasdaq: regn) and alnylam pharmaceuticals, inc. (nasdaq: alny) announced today preliminary phase 1 data supporting the clinical advancement of aln-hsd, an investigational rnai therapeutic targeting hsd17b13 in development for the treatment of nonalcoholic steatohepatitis (nash).
ALNY Ratings Summary
ALNY Quant Ranking